Pdt Partners, LLC Fulcrum Therapeutics, Inc. Transaction History

Pdt Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.7 - $12.0 $331,770 - $594,216	49,518 New	49,518 $467,000
Q1 2023 May 15, 2023	SELL	$2.83 - $13.99 $36,224 - $179,072	-12,800 Reduced 30.92%	28,603 $81,000
Q4 2022 Feb 14, 2023	BUY	$5.01 - $8.35 $207,429 - $345,715	41,403 New	41,403 $301,000
Q4 2021 Feb 14, 2022	SELL	$14.0 - $28.44 $189,322 - $384,594	-13,523 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$7.28 - $30.97 $32,592 - $138,652	-4,477 Reduced 24.87%	13,523 $381,000
Q2 2021 Aug 16, 2021	SELL	$8.09 - $12.0 $18,954 - $28,116	-2,343 Reduced 11.52%	18,000 $189,000
Q1 2021 May 17, 2021	SELL	$10.94 - $15.32 $36,834 - $51,582	-3,367 Reduced 14.2%	20,343 $240,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $13.4 $185,886 - $317,714	23,710 New	23,710 $278,000

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $169M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.